Skip to main content

Table 4 F-CP levels of patients with T2DM at 3, 6, and 12 months after MSCs therapy

From: Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Follow-up (months) Test for heterogeneity Analysis model Test for overall effect WMD or SMD 95% CI
I2 (%) P Z P
3 29 0.24 Fixed 1.65 0.10 0.46 (−0.09, 1.01)
6 42 0.19 Fixed 2.94 0.003 0.85 (0.29, 1.42)
12 0 0.96 Fixed 2.18 0.03 0.62 (0.06, 1.17)
  1. Abbreviations: F-CP fasting C-peptide, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference